首页> 外文期刊>BMC Women s Health >Cryo-thawed embryo transfer: natural versus artificial cycle. A non-inferiority trial.(ANTARCTICA trial)
【24h】

Cryo-thawed embryo transfer: natural versus artificial cycle. A non-inferiority trial.(ANTARCTICA trial)

机译:冷冻融化的胚胎移植:自然循环与人工循环。非自卑感试验(ANTARCTICA试验)

获取原文
           

摘要

Background Frozen thawed embryo transfer (FET) is a cost- effective adjunct to IVF or IVF-ICSI treatment. In order to optimize treatment outcome, FET should be carried out during a period of optimal endometrial receptivity. To optimize implantation several methods for endometrium preparation have been proposed. In natural cycle FET (NC-FET), the endometrium develops under endogenous hormonal stimulation. The development of the dominant follicle and endometrium is monitored by ultrasound and FET is timed after triggering ovulation induction or determination of the spontaneous LH surge. In an artificial cycle FET (AC-FET) estrogens and progesterone are administered to prepare the endometrium for implantation. While the currently available data show no significant difference in pregnancy rates between these methods, well designed randomized controlled trials are lacking. Moreover there is little literature on difference in cancellation rates, cost-efficiency and adverse events. Methods and design In this randomized, multi-centre, non-inferiority trial we aim to test the hypothesis that there is no significant difference in live birth rates between patients undergoing NC-FET versus AC-FET. The primary outcome will be live birth rate per embryo transfer procedure. Secondary outcomes will be ongoing and clinical pregnancy rate, cancellation rate, (serious) adverse events and cost-efficiency. Based on a live birth rate of 20% and a minimal clinical important difference of 7,5% (one-sided alpha 2,5%, beta 20%) a total of 1150 patients will be needed. Analyzes will be performed using both per protocol as well as intention to treat analyses. Discussion This prospective, randomized, non –inferiority trial aims to address the hypothesis that there is no significant difference in live birth rates between patients undergoing NC-FET versus patients undergoing AC-FET. Moreover it addresses cost-efficiency as well as the perceived burden of both treatments. Trial register Netherlands trial register (NTR): 1586
机译:背景技术冻融胚胎移植(FET)是IVF或IVF-ICSI治疗的经济有效的辅助手段。为了优化治疗效果,应在最佳子宫内膜接受度期间进行FET。为了优化植入,已经提出了几种用于子宫内膜制备的方法。在自然周期场效应管(NC-FET)中,子宫内膜在内源性激素刺激下发育。通过超声监测主要卵泡和子宫内膜的发育,并在触发排卵诱导或确定自发性LH激增后计时FET。在人工循环FET(AC-FET)中,雌激素和孕酮被给药以准备植入子宫内膜。尽管目前可获得的数据显示这些方法之间的妊娠率没有显着差异,但缺乏设计良好的随机对照试验。此外,关于取消率,成本效率和不良事件差异的文献很少。方法和设计在这项随机,多中心,非劣效性试验中,我们旨在检验以下假设:接受NC-FET的患者与AC-FET的患者的活产率没有显着差异。主要结果将是每个胚胎移植过程的活产率。次要结果将是正在进行的以及临床妊娠率,取消率,(严重)不良事件和成本效益。基于20%的活产率和7.5%的最小临床重要差异(单侧alpha为2.5%,beta为20%),总共需要1150名患者。将使用每个方案以及治疗分析的意图来进行分析。讨论这项前瞻性,随机,非劣效性试验旨在解决以下假设:接受NC-FET的患者与接受AC-FET的患者的活产率没有显着差异。此外,它还解决了成本效率以及两种治疗方法的负担。试用注册荷兰试用注册(NTR):1586

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号